JP2023542107A - ＳＡＲＳ－ＣｏＶ－２を標的とするシングルドメイン抗体 - Google Patents

ＳＡＲＳ－ＣｏＶ－２を標的とするシングルドメイン抗体 Download PDF

Info

Publication number
JP2023542107A
JP2023542107A JP2023516720A JP2023516720A JP2023542107A JP 2023542107 A JP2023542107 A JP 2023542107A JP 2023516720 A JP2023516720 A JP 2023516720A JP 2023516720 A JP2023516720 A JP 2023516720A JP 2023542107 A JP2023542107 A JP 2023542107A
Authority
JP
Japan
Prior art keywords
seq
cdr3
single domain
cdr2
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023516720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542107A5 (https=
Inventor
フォ、ジェンドン
オーウェンズ、レイモンド
ネイスミス、ジェイムズ
Original Assignee
ザ ロザリンド フランクリン インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2014451.5A external-priority patent/GB202014451D0/en
Priority claimed from GBGB2014453.1A external-priority patent/GB202014453D0/en
Priority claimed from GBGB2108319.1A external-priority patent/GB202108319D0/en
Application filed by ザ ロザリンド フランクリン インスティテュート filed Critical ザ ロザリンド フランクリン インスティテュート
Publication of JP2023542107A publication Critical patent/JP2023542107A/ja
Publication of JP2023542107A5 publication Critical patent/JP2023542107A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023516720A 2020-09-14 2021-09-14 ＳＡＲＳ－ＣｏＶ－２を標的とするシングルドメイン抗体 Withdrawn JP2023542107A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2014453.1 2020-09-14
GBGB2014451.5A GB202014451D0 (en) 2020-09-14 2020-09-14 Single domain antibodies
GB2014451.5 2020-09-14
GBGB2014453.1A GB202014453D0 (en) 2020-09-14 2020-09-14 Linker
GBGB2108319.1A GB202108319D0 (en) 2021-06-10 2021-06-10 Single domain antibodies
GB2108319.1 2021-06-10
PCT/GB2021/052383 WO2022053839A1 (en) 2020-09-14 2021-09-14 Single domain antibodies that target sars-cov-2

Publications (2)

Publication Number Publication Date
JP2023542107A true JP2023542107A (ja) 2023-10-05
JP2023542107A5 JP2023542107A5 (https=) 2024-09-25

Family

ID=77951755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516720A Withdrawn JP2023542107A (ja) 2020-09-14 2021-09-14 ＳＡＲＳ－ＣｏＶ－２を標的とするシングルドメイン抗体

Country Status (7)

Country Link
US (1) US20230374116A1 (https=)
EP (1) EP4211157A1 (https=)
JP (1) JP2023542107A (https=)
KR (1) KR20240102916A (https=)
AU (1) AU2021339978A1 (https=)
CA (1) CA3192456A1 (https=)
WO (1) WO2022053839A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813759B (zh) * 2022-03-21 2025-11-28 中国科学院微生物研究所 纳米抗体r14的构建体及其应用
CN114736293B (zh) * 2022-06-14 2022-09-02 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用
CN117603358B (zh) * 2023-02-24 2024-11-01 中国科学院微生物研究所 一种广谱新型冠状病毒的双特异性抗体
CN118255878A (zh) * 2024-04-15 2024-06-28 深圳细胞谷生物医药有限公司 SARS-CoV-2驼源纳米抗体或其抗原结合片段、及其组合物和应用
GB202413879D0 (en) 2024-09-20 2024-11-06 Rosalind Franklin Inst Single domain antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법

Also Published As

Publication number Publication date
WO2022053839A1 (en) 2022-03-17
EP4211157A1 (en) 2023-07-19
US20230374116A1 (en) 2023-11-23
KR20240102916A (ko) 2024-07-03
AU2021339978A9 (en) 2024-10-10
AU2021339978A1 (en) 2023-05-04
CA3192456A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
JP7727387B2 (ja) 新規の抗ｃｄ３９抗体
JP2023542107A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とするシングルドメイン抗体
JP7773981B2 (ja) 新型ポリペプチド複合物
WO2021244089A1 (zh) 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用
JP6050747B2 (ja) インフルエンザ受動免疫化に有用な抗体
CN113583116A (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
US20230242624A1 (en) HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
KR20160119196A (ko) IgA 다중-특이적 결합 분자
EP4188960A1 (en) Materials and methods for multidirectional biotransportation in virotherapeutics
US20230357364A1 (en) Covid-19 antibodies and uses thereof
CN115515976A (zh) 冠状病毒抗体
US20240270826A1 (en) Antibodies that bind sars-cov-2 spike protein
JP2023534922A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
Song et al. Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2
Rathore et al. Recent developments toward antibody engineering and affinity maturation
EP3271388A1 (en) Antibodies specific to glycoprotein (gp) of ebola virus and uses for the treatment and diagnosis of ebola virus infection
CN116096402A (zh) 与抗人冠状病毒的中和抗体相关的方法和组合物
US20240228595A1 (en) Methods for Monoclonal Antibody Generation
CN116554340A (zh) 新型长效化和高活性且更安全的抗体构建体
CN117042799A (zh) 靶向sars-cov-2的单结构域抗体
US20240401239A1 (en) Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CA3102329C (en) Novel anti-cd39 antibodies
CA3267635A1 (en) Antivirals against human parainfluenza virus
EP4594348A1 (en) Antivirals against human parainfluenza virus
WO2023288078A1 (en) Coronavirus antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230516

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240913

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250731